Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting in Patients With Left Main Disease With or Without Diabetes: Findings From a Pooled Analysis of 4 Randomized Clinical Trials: @CircAHA
🥸wow: more on left main+diabetes: PCI vs CABG!
😱 Summary
👇👇👇
1/ 🥸 Left main coronary artery disease and diabetes are associated with substantial cardiovascular morbidity and mortality.
2/ 🥸 Yet, long-term outcomes for patients with left main disease and diabetes undergoing PCI compared with CABG remain unclear.
3/ 🥸 Previous subgroup studies of individual randomized trials have attempted to address this issue but had limited power.
4/ 🥸 Moreover, registry-based studies have been constrained by biases and confounding.
5/🥸 Previous trials suggested that diabetes might modulate clinical outcomes, with a lower 5-year mortality rate in CABG patients but similar rates after PCI and CABG in non-diabetic patients.
6/ 🥸 The objective was to use pooled patient-level data from 4 major trials comparing PCI with CABG in patients with left main disease to examine outcomes in patients with versus without diabetes.
7/ 🥸 Data from SYNTAX, PRECOMBAT, NOBLE, and EXCEL trials were pooled and analyzed.
😱 Amazing!
8/ 🥸 Patients were categorized by the presence or absence of diabetes at baseline.
9/ 🥸 The primary endpoint was all-cause death through 5 years, with secondary endpoints including cardiovascular death, MI, stroke, and others.
10/ 🥸 Mortality rate at 10 years was also analyzed from 2 of the trials.
11/ 🥸 Statistical analysis involved comparing baseline characteristics and estimating time-to-event outcomes with Cox Proportional Hazards models.
🥸 Interactions between treatment effects and diabetes presence were evaluated for risk differences.
12/ 🥸 Exploratory analyses further stratified outcomes by diabetes treatment and compared event rates by treatment modality.
😱 The relationship between cardiovascular death and SYNTAX score in patients with and without diabetes was explored.
13/ 🥸 Among 4,394 patients with left main disease, nearly all had data on diabetes status, and showed 1,104 (25.1%) had diabetes, with 22.6% on insulin therapy.
14/ 🥸 Baseline characteristics, such as hypertension and dyslipidemia and multiple comorbidities, were more common in diabetic patients.
😱See table 👇
15/ 🥸 Diabetic patients experienced higher all-cause and cardiovascular death rates over 5 years compared to non-diabetics.
16/ 🥸 The risk remained even after adjusting for baseline differences, emphasizing the impact of diabetes on outcomes.
17/ 🥸 Despite diabetes, mortality rates after PCI and CABG were similar, with no significant difference observed
😱Look at this 👇👇👇
18/ 🥸 High SYNTAX scores in diabetics suggested an greater risk of cardiovascular death with PCI than CABG.
19/ 🥸 Across all patients, PCI was associated with lower early stroke risk but higher rates of MI and revascularization compared to CABG.
20/ 🥸 The findings highlight the need for a balanced discussion on revascularization strategies, especially in diabetic patients with left main disease.
21/ 🥸 This comprehensive analysis provides insights on shared decision-making in clinical practice, focusing on the trade-offs between PCI and CABG for left main disease +/- DM.
😱Excellent work...This needs an editorial @CircAHA
🥸 Have a nice day everyone!
• • •
Missing some Tweet in this thread? You can try to
force a refresh
Critical Care Management of Patients After Cardiac Arrest: A Scientific Statement From the American Heart Association and Neurocritical Care Society: @CircAHA
🥸Great work: @AHA_Research @AHA_AcuteCVCare
😱Let's summarize: Happy Sunday :)
👇👇👇
1/🥸 Cardiac Arrest Prevalence: Over 600,000 individuals in the US experience cardiac arrest annually.
😱This is a significant public health problem.
2/ 🥸 Worldwide Incidence: Globally, cardiac arrest occurs in 30 to 97 individuals per 100,000 population.
Patients with subclinical atrial fibrillation can benefit from apixaban to reduce the risk of stroke and systemic thromboembolism.
2/CARDIA-SSBP:
🥸The decline in SBP with a low-sodium diet was independent of hypertension status and anti-hypertensive medication use, consistent across subgroups, and did not result in excess adverse
3/ CRHCP:
🥸Intensive BP lowering (target BP < 130/80 mm Hg) significantly reduced risk of all-cause dementia among patients with hypertension, supporting the use of intensive hypertension treatment to reduce the burden of dementia.
Semaglutide and Cardiovascular Outcomes
in Obesity without Diabetes: @NEJM
The select trial: #AHA23
🥸Wow! @AHA_Research
😱Now on the stage in main event
😱Let's get the highlights
👇👇👇
1.🥸 GLP-1 receptor agonists are known for cardiovascular benefits in type 2 diabetes.
2.🥸 The SELECT trial tested semaglutide, a potent member of GLP-1 class of drugs, for cardiovascular risk in overweight individuals without diabetes history.
Impact of Complete Revascularization in the ISCHEMIA Trial: @JACCJournals
How do you interpret the results of this ischemia sub-study? The devil is in the detail. 😱
Good morning: 🥸
Below 👇👇
🥸1. In the ISCHEMIA study, 43.4% and 58.4% of revascularization procedures met the criteria for Achieved Complete Revascularization and Functional Complete Revascularization, respectively.
🥸2. For the entire cohort, these rates were almost the same, with 19.1% of patients only receiving medical treatment.